Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

BioDuro and Cenra launch joint venture to expand resilient global API manufacturing capacity: Irvine Californa Thursday, March 5, 2026, 14:00 Hrs [IST] BioDuro, a globally trusted ...

Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade Two new ...